Findings
========

Background
----------

Human metapneumovirus (hMPV) is a member of the *Pneumoviridae* subfamily of the *Paramyxoviridae*\[[@B1]\]. hMPV infects half of all infants under the age of 1 year and almost all children have been infected by the age of 10 years \[[@B2],[@B3]\]. hMPV causes acute respiratory disease in children worldwide \[[@B4]-[@B6]\]. Currently, there are no vaccines or targeted therapies for hMPV infection. RNA interference (RNAi) is a mechanism of post-transcriptional gene silencing found in almost all eukaryotes and is triggered by endogenous small non-coding microRNAs (miRNAs) or small interfering RNAs (siRNAs) \[[@B7]\]. The recently development of synthetic sequence-specific siRNAs has allowed a variety of host and pathogen genes to be targeted for mRNA cleavage, effectively silencing or significantly reducing gene expression \[[@B7]\]. Reports for RSV and hMPV suggest that RNAi can inhibit viral mRNA expression, and is a potentially effective therapy for respiratory infections \[[@B8]-[@B13]\].

siRNA molecules targeting the nucleoprotein (N) and phosphoprotein (P) mRNA of hMPV have been found effective at inhibiting the hMPV genome \[[@B13]\]. Here we have designed and validated a siRNA molecule against the G gene, which encodes a principal attachment protein required for replication *in vivo* and also identified as a type I interferon (IFN) antagonist \[[@B14]\].

Design and validation of siRNA against the G gene
-------------------------------------------------

The hMPV isolate CAN97-83 G gene was used as target sequence to design siRNA molecules by Dharmacon, using their algorithm and ON-TARGETplus ® sense strand modification to avoid off-target effects. Two siRNA molecules were chosen for analysis and validation:

G1: sense - GCUCAAAGCAAGAGUGAAA

G2: sense - AGGUGAAAGUAGAGAACAUUU

The molecules do not target all isolates of hMPV as identified by BLAST, due to the high level of divergence in the G sequence \[[@B6],[@B15]\]. A mis-matched siRNA molecule (siMM; sense - CUAAAGUGGUAGUUGAUAUUU) was also generated as a control for the effect of transfection and off-target effects. hMPV (CAN97-83) was propagated in LLC-MK2 cells, concentrated through a 30%/60% w/v sucrose gradient, pelleted by centrifugation at 12,000 x *g* for 2 hours at 4 °C, and the viral titre quantified using a TCID~50~ assay and anti-hMPV M monoclonal antibody (Chemicon) to identify positive cells. Preliminary transfection experiments (not shown) using a fluorescein labeled RNAi delivery control (Mirus) demonstrated that transfection of 200 mM siRNA resulted in 100% transfection efficiency at 24 h. Preliminary infection experiments established that 100% of cells were infected by 24 h post-infection (pi) when exposed to hMPV at a multiplicity of infection (MOI) of 2 in the absence of trypsin.

A549 cells were transfected with siG1, siG2 or siMM 6 h prior to infection with hMPV. At 12 h and 24 h pi, total RNA was extracted from cells using TRIzol/chloroform separation and RNeasy spin columns (QIAGEN). cDNA was generated using superscript III reverse transcriptase (Invitrogen) and oligo d(T)~20~ primers to select for mRNA. Quantitative (q) RT-PCR was performed to quantify G mRNA reduction using the following oligonucleotides: forward primer 3′- GCAGCAATAGACATGCTCAAA-5′, reverse primer 3′-GAGCTGGTGTGGTGTTCTGA-5′, hybridization probe 3′-HEX-AAATCGTGTGGCACGTAGCAAATGC-BHQ-5′. N mRNA was also quantified using the following oligonucleotides: forward primer 3′- TTACGGTGCTGGTCAAACAA-5′, reverse primer 3′-TTTGGGCTTTGCCTTAAATG-5′, hybridization probe 3′-HEX-CTATGACCTGGTGCGAGAAATGGGC-BHQ-5′. qPCR was performed using QuantiTECT mastermix (QIAGEN) and a Rotorgene 3000 (Roche). G and N mRNA in hMPV-infected cells was quantified in relation to β-actin mRNA for each sample and in relation to untransfected cells using the ΔΔCt formula. The ΔΔCt value was then converted to percent reduction of G or N mRNA (Applied Biosystems Technotes vol 15\[[@B2]\] p. 10).

At 12 h pi, siG1 and siG2 resulted in 83.7% and 85.2% G mRNA reduction respectively compared to siMM (not shown). In three independent experiments, 200 mM siG2 resulted in a mean G mRNA reduction of 88% (12% remaining; *P* = 3.4 x 10^-4^ compared to siMM) at 24 h pi in infected A549 cells (Figure [1a](#F1){ref-type="fig"}). siG1 was not as effective at reducing G mRNA at 24 h pi (29% remaining), and was therefore not used for subsequent experiments. The effect of siG1 and siG2 on hMPV N was negligible (\<3%), indicating that other viral genes were not affected (Figure [1b](#F1){ref-type="fig"}).

![**The effect of prior siG1 and siG2 transfection of A549 cells on G and N mRNA 24 h post-infection with hMPV at a MOI of 2.** (**a**) hMPV G mRNA was significantly reduced by siG2 compared to cells either transfected with siMM (\**P* = 1.6 x 10^-5^, t-test) or not transfected. siG1 was not as effective at reducing G mRNA and subsequently was not used for experimentation. (**b**) siG1, siG2 and siMM did not reduce nucleoprotein (N) mRNA. hMPV N and G mRNA were quantified by RT-qPCR. Data was normalised to β-actin and expressed relative to untreated A549 cells.](1743-422X-9-105-1){#F1}

We had planned to investigate the effect of siG2 transfection on G protein expression. An antibody to detect G protein in lysed cell preparations has not been described in the literature, nor is commercially available. Affinity purified rabbit antisera were generated to a G peptide considered suitable for this purpose. However, the sera detected only a \~32 kDa band, which may have been a truncated form of G, and did not detect the non-truncated 90 kDa G protein. Due to the ambiguity of G protein detection we were not able to quantify the effect of G mRNA reduction on G protein expression. However, other studies that involve the validation of siRNA molecules against viral mRNAs demonstrate that a reduction in target mRNA similar to that demonstrated here correlate to a significant reduction in protein \[[@B9],[@B10],[@B16]\].

Knockdown of G does not modulate viral growth in vitro or the induction of type I interferon
--------------------------------------------------------------------------------------------

Triplicate cultures of A549 cells were transfected with siG2, siMM or untransfected, as described above, and infected with hMPV at a MOI of 0.1. Cell supernatants were collected on days 0, 1, 3 and 5 pi, and the titres of shed virus quantified by TCID~50~ assay. Reduction of G mRNA was confirmed at day 1 pi (not shown). There was no significant difference in the titres of shed virus between cells transfected with siMM, siG or untransfected, which indicated that the growth of hMPV *in vitro* was not affected by G knockdown (Figure [2](#F2){ref-type="fig"}; ANOVA). This correlates to a study using recombinant (r) hMPVΔG in which deletion of G did not attenuate viral growth in LLC-MK2 cells \[[@B17]\]. This differs to a report in which rhMPVΔG displayed a reduction in viral titre by one third to half a log after 24 h of infection in A549 cells \[[@B14]\].

![**The effect of siG2 and siMM transfection 6 h prior to infection of A549 cells with hMPV at a MOI of 0.1.** Viral supernatants were collected on the indicated days and the shed hMPV quantified using immunostaining and expressed as TCID~50~/ml. A significant reduction in G mRNA did not affect hMPV shed over 5 days pi.](1743-422X-9-105-2){#F2}

It has been reported that deletion of G from rhMPV results in an increase in chemokine and type I IFN production in infected airway epithelial cells \[[@B14]\]. Here we investigated if knockdown of G by siRNA would also result in an increase in type I IFN induction. A549 cells were transfected with siMM or siG2, or not transfected and 6 h later infected at a MOI of 2 with hMPV, or mock-infected with media. UV-inactivated hMPV was used as a control for IFN induction. 24 h pi cells were harvested and total RNA extracted as described above. RT-qPCR was performed to quantify IFN-β and -α mRNA using primers and molecular probes previously described \[[@B18]\]. G mRNA knockdown by 88-92% was confirmed by qPCR. The siMM and siG2 molecules alone did not induce either IFN-α or -β indicating no off-target effects on type I IFN induction (Figure [3](#F3){ref-type="fig"} a and b, first two bars). hMPV infection alone did not induce IFN-α and did induce IFN-β by 5850-fold over uninfected cells. Transfection with siMM prior to hMPV infection (siMM + hMPV) dampened IFN-β induction indicating some effect of transfection on the cells. However, the knockdown of G resulted in a marginally significant increase in IFN-β mRNA induction compared to hMPV infection alone (*P* = 0.03). A more significant increase was observed compared to siMM + hMPV (*P* = 0.02), although the difference in fold induction between these two treatments, from 3000-fold (siMM) to 8500-fold (siG2), was only 2.85, which may be of only marginal biological significance. ELISA was performed on the cell supernatants collected from transfected and/or infected cells at 24 h, 48 h and 72 h pi. A reduction of G mRNA did not result in a significant increase in secreted IFN-β at any time (Figure [3c](#F3){ref-type="fig"}; *P* \> 0.05). In fact, a slight reduction in secreted IFN-β is observed, which may be the result of transfection. This suggests that although there is a moderate increase in IFN-β mRNA when G mRNA is reduced, this does not result in an increase in IFN-β protein secreted from infected cells. This observation differs from another study in which there was a significant increase in IFN-α/β secretion from infected cells when G was deleted from rhMPV. ELISA (not shown) for IFN-α was conducted and showed no detectable induction as correlated to qPCR results (Figure [3a](#F3){ref-type="fig"}). Our growth curves for hMPV are similar to those of Biacchesi et al., (2004), which also suggest that a knockdown of G does not induce type I IFN, which may attenuate viral growth.

![**The effect of G knockdown on type I Interferon induction.** A549 cells were transfected with siMM, siG2 or were not transfected prior to infection with hMPV at a MOI of 2, or mock infection with media. UV-inactivated hMPV was used as a control for interferon induction. Transcription of mRNA encoding human IFN-α (**a**) and IFN-β (**b**) was measured by RT-qPCR 24 h post-infection. There was a moderately significant increase in IFN-β mRNA in siG2 transfected cells compared to untransfected cells (\*P = 0.03; t-test) and cells transfected with siMM (\*\*P = 0.02; t-test) prior to hMPV infection. Data was normalised to β-actin and expressed relative to uninfected cells. (**c**) A reduction in G did not affect IFN-β secretion from cells transfected with either siMM or siG2 prior to hMPV infection, compared to untransfected and infected cells. Supernatants were collects on days 1, 2 and 3 post-infection for ELISA analysis.](1743-422X-9-105-3){#F3}

The effect of G on type I IFN induction was also investigated using an adenovirus which expressed the hMPV G protein (Ad-hMPV-G; gift from R. Tripp, University of Georgia, Athens, USA). A549 cells were infected with Ad-hMPV G or Ad-Lac Z as a control, at a MOI of 1. After 1 h adsorbtion at 37 °C, virus inoculum was replaced with growth media and infected cells collected for mRNA analysis at 6 h and 12 h pi. G protein expression by adenovirus did not significantly affect type I IFN mRNA levels compared to control (Figure [4](#F4){ref-type="fig"}).

![**The effect of Ad-hMPV-G expression on type I IFN induction.** A549 cells were infected with Ad-hMPV-G or Ad-lac z (MOI 1). Cells were collected at the indicated times after infection for the quantification of IFN α/β mRNA transcription by RT-qPCR. hMPV G expression did not affect IFN-α or --β expression at 6 h or 12 h post-infection](1743-422X-9-105-4){#F4}

In summary, we have designed and validate a siRNA molecule that is effective against the G gene of hMPV *in vitro.* A significant reduction in G mRNA did not reduce viral growth *in vitro* or induce a significant type I IFN response, suggesting that G may not be a significant type I IFN antagonist, and other hMPV proteins may play a role in modulating type I IFN induction. However hMPV G may still be a valid target for RNAi as G is required for viral replication *in vivo*\[[@B17]\].
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